Baike Biological: Clinical trial application for adolescent and adult DTaP vaccine approved.

Baike Biotech Announcement: The company recently received the "Drug Clinical Trial Approval Notice" of the adsorbed non-cellular combined vaccine for pertussis, diphtheria, and tetanus issued by the National Medical Products Administration. This vaccine is a vaccine that can simultaneously prevent pertussis, diphtheria, and tetanus in adolescents and adults, with the target population being individuals aged 10 and above. If the clinical trials are successfully completed and approved for market, it will further improve the company's vaccine research and development pipeline, enrich the company's combined vaccine product matrix, and help optimize the company's product structure and promote the comprehensive development of its core business.